Market Trends of North America Alpha-Glucosidase Inhibitors Industry
Rising Diabetes Prevalence in North America Region
According to the National Diabetes Statistics Report 2022, approximately 37.5 million people, or approximately 11.3% of the US population, had diabetes. People who are overweight are more likely to develop prediabetes, which can progress to type-2 diabetes, putting them at risk for complications, acute and long-term complications, and death. Obesity, an unhealthy diet, and a sedentary lifestyle are all contributing to an increase in newly diagnosed type-1 and type-2 diabetes cases. The increased prevalence of diabetic patients and global healthcare expenditure are indicators of a greater proclivity for diabetic drugs. Type-2 diabetes (T2D) is becoming more common and is linked to an increased risk of cardiovascular and renal disease. Meglitinides are oral medications used to treat type-2 diabetes in conjunction with lifestyle changes. They work by stimulating insulin release from pancreatic beta cells, which lowers blood glucose levels.
The North American region has witnessed an astounding increase in the prevalence of diabetes in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses than non-diabetic people. Patients with type-2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or the ingestion of additional carbohydrates.
The United States is Expected to Dominate North America Alpha-Glucosidase Inhibitors Market.
Acarbose (Precose), voglibose, and miglitol (Glyset) are medications in the alpha-glucosidase inhibitors class of drugs. These drugs help keep the amount of glucose in the blood from rising too fast after meals. Alpha-glucosidase inhibitors help lower postprandial diabetes. These medications reduce the levels of glycosylated hemoglobin and lower the concentration of postprandial insulin. Regulation of post-meal hyperglycemia is vital, as it is associated with the development of complications and also increases the risk of heart problems.
Type-2 diabetes is increasingly prevalent and associated with an increased risk for cardiovascular and renal disease. Alpha-glucosidase inhibitors may also be used in patients with impaired glucose tolerance to delay the occurrence of type-2 diabetes mellitus in these patients. They are particularly useful for patients who are at risk of hypoglycemia or lactic acidosis and are not suitable candidates for other antidiabetic drugs such as sulfonylureas and metformin. Alpha-glucosidase inhibitors are FDA-approved for the treatment of type-2 diabetes mellitus.
In April 2021, WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors to work on a shared vision of reducing the risk of diabetes and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable, and quality treatment and care.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
